Literature DB >> 25955111

miR-494 suppresses the progression of breast cancer in vitro by targeting CXCR4 through the Wnt/β-catenin signaling pathway.

Lingqin Song1, Di Liu1, Baofeng Wang1, Jianjun He2, Shuqun Zhang1, Zhijun Dai1, Xiaobin Ma1, Xijing Wang1.   

Abstract

Breast cancer is the most common cancer among women with a high mortality worldwide, which is mainly due to tumor invasion and metastasis. Previous studies have reported that microRNA-494 (miR-494) is downregulated in breast cancer cells. The present study investigated the role of miR-494 in the progression of breast cancer and the underlying mechanisms. The levels of miR-494 were analyzed in several breast cancer cell lines by quantitative reverse transcription PCR (qRT-PCR). The miR-494 mRNA levels were significantly lower in the malignant breast cancer cells than the level in the non-malignant normal breast epithelial cells. miR-494 mimic transfection upregulated the expression levels of E-cadherin, yet downregulated N-cadherin, vimentin and α-smooth muscle actin (α-SMA) in the breast cancer cells. As expected, the expression of these markers in breast cancer cells transfected with miR-494 inhibitors exhibited the opposite variation trend. MTT and Transwell assays showed that cell proliferation and invasion were both significantly suppressed by miR-494 mimics, and were significantly promoted by miR-494 inhibitors. The protein expression level of chemokine (C-X-C motif) receptor 4 (CXCR4) in the breast cancer cells was significantly inhibited by miR-494 mimics, and enhanced by miR-494 inhibitors. Yet, the mRNA level of CXCR4 was barely affected by miR-494 mimics or inhibitors. Dual-luciferase assay confirmed that miR-494 directly interacted with the 3'-untranslated region of CXCR4 mRNA by dual-luciferase assay. The miR-494 mimics also significantly inhibited the transcription levels of β-catenin, LEF1, CD44 and cyclin-D1, which was similar to the effect of siRNA targeted to CXCR4. In conclusion, miR-494 suppresses the progression of breast cancer through the Wnt/β-catenin signaling pathway, which is mediated by CXCR4.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25955111     DOI: 10.3892/or.2015.3965

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  24 in total

1.  Acute Hepatitis C Virus Infection Induces Consistent Changes in Circulating MicroRNAs That Are Associated with Nonlytic Hepatocyte Release.

Authors:  Ramy El-Diwany; Lisa N Wasilewski; Kenneth W Witwer; Justin R Bailey; Kimberly Page; Stuart C Ray; Andrea L Cox; David L Thomas; Ashwin Balagopal
Journal:  J Virol       Date:  2015-07-08       Impact factor: 5.103

Review 2.  Onco-GPCR signaling and dysregulated expression of microRNAs in human cancer.

Authors:  Nijiro Nohata; Yusuke Goto; J Silvio Gutkind
Journal:  J Hum Genet       Date:  2016-10-13       Impact factor: 3.172

3.  MicroRNAs are key regulators of hepatocellular carcinoma (HCC) cell dissemination-what we learned from microRNA-494.

Authors:  Margarita González-Vallinas; Kai Breuhahn
Journal:  Hepatobiliary Surg Nutr       Date:  2016-08       Impact factor: 7.293

4.  microRNA-494 is a potential prognostic marker and inhibits cellular proliferation, migration and invasion by targeting SIRT1 in epithelial ovarian cancer.

Authors:  Aijun Yang; Xuenan Wang; Chunna Yu; Zhenzhen Jin; Lingxia Wei; Jinghe Cao; Qin Wang; Min Zhang; Lin Zhang; Lei Zhang; Cuifang Hao
Journal:  Oncol Lett       Date:  2017-06-30       Impact factor: 2.967

Review 5.  Role of microRNAs in chemoresistance.

Authors:  Peter Magee; Lei Shi; Michela Garofalo
Journal:  Ann Transl Med       Date:  2015-12

6.  miR-494 inhibits cervical cancer cell proliferation through upregulation of SOCS6 expression.

Authors:  Lei Cheng; Beihua Kong; Ying Zhao; Jie Jiang
Journal:  Oncol Lett       Date:  2017-12-19       Impact factor: 2.967

7.  miR-494 inhibits ovarian cancer cell proliferation and promotes apoptosis by targeting FGFR2.

Authors:  Xiaojuan Zhao; Yun Zhou; Y U Chen; Feng Yu
Journal:  Oncol Lett       Date:  2016-05-05       Impact factor: 2.967

8.  MicroRNA-494 inhibits proliferation and metastasis of osteosarcoma through repressing insulin receptor substrate-1.

Authors:  Xiaodong Zhi; Kai Wu; Deshui Yu; Yansong Wang; Yang Yu; Peng Yan; Gang Lv
Journal:  Am J Transl Res       Date:  2016-08-15       Impact factor: 3.940

9.  Simvastatin improves the homing of BMSCs via the PI3K/AKT/miR-9 pathway.

Authors:  Weidong Bing; Xinyan Pang; Qingxi Qu; Xiao Bai; Wenwen Yang; Yanwen Bi; Xiaolu Bi
Journal:  J Cell Mol Med       Date:  2016-02-12       Impact factor: 5.310

10.  Tumor-suppressing roles of miR-214 and miR-218 in breast cancer.

Authors:  Bo Liu; Yanfeng Tian; Fang Li; Zengren Zhao; Xia Jiang; Congjie Zhai; Xiaodong Han; Like Zhang
Journal:  Oncol Rep       Date:  2016-04-15       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.